Virologic and immunologic response to HAART, by age and regimen class

Keri N. Althoff, Amy C. Justice, Stephen J. Gange, Steven G. Deeks, Michael S. Saag, Michael J. Silverberg, M. John Gill, Bryan Lau, Sonia Napravnik, Ellen Tedaldi, Marina B. Klein, Kelly A. Gebo

Research output: Contribution to journalArticlepeer-review

91 Scopus citations


Objective: To determine the impact of age and initial HAART regimen class on virologic and immunologic response within 24 months after initiation. Design: Pooled analysis of data from 19 prospective cohort studies in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Methods: Twelve thousand, one hundred and ninety-six antiretroviral-naive adults who initiated HAART between 1998 and 2008 using a boosted protease inhibitor-based regimen or a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen were included in our study. Discrete time-to-event models estimated adjusted hazard odds ratios (aHOR) and 95% confidence intervals (CIs) for suppressed viral load (≤500 copies/ml) and, separately, at least 100cells/μl increase in CD4 cell count. Truncated, stabilized inverse probability weights accounted for selection biases from discontinuation of initial regimen class. Results: Among 12 196 eligible participants (mean age = 42 years), 50% changed regimen classes after initiation (57 and 48% of whom initiated protease inhibitor and NNRTI-based regimens, respectively). Mean CD4 cell count at initiation was similar by age. Virologic response to treatment was less likely in those initiating using a boosted protease inhibitor [aHOR = 0.77(0.73, 0.82)], regardless of age. Immunologic response decreased with increasing age [18-<30: ref;30-<40: aHOR = 0.92 (0.85, 1.00); 40-<50: aHOR = 0.85 (0.78, 0.92); 50-<60: aHOR = 0.82 (0.74, 0.90);>60: aHOR = 0.74 (0.65, 0.85)], regardless of initial regimen. Conclusion: We found no evidence of an interaction between age and initial anti- retroviral regimen on virologic or immunologic response to HAART; however, decreased immunologic response with increasing age may have implications for age-specific when-to-start guidelines.

Original languageEnglish (US)
Pages (from-to)2469-2479
Number of pages11
Issue number16
StatePublished - Oct 23 2010


  • Age
  • CD4 lymphocyte count
  • HIV
  • Viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Virologic and immunologic response to HAART, by age and regimen class'. Together they form a unique fingerprint.

Cite this